FATE - Company ID 0001434316
The table below shows FATE THERAPEUTICS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $1.30M | $1.74M | $1.91M | $1.63M | $3.07M | $6.77M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $24.70M | $25.84M | $27.43M | $29.14M | $34.65M | $34.60M |
FATE THERAPEUTICS INC reported annual revenue of $6.65M for fiscal year 2025. That is down 51.2% from $13.63M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $4.40M (FY 2016) to $6.65M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $9.60M |
| $10.64M |
| $11.45M |
| $13.77M |
| $20.80M |
| $17.25M |
| Operating income | -$33.00M | -$34.73M | -$36.97M | -$41.28M | -$52.38M | -$45.08M |
| Income tax | - | - | - | - | - | - |
| Net income | -$31.21M | -$32.25M | -$34.07M | -$37.62M | -$47.68M | -$38.43M |
| EPS (diluted) | -$0.26 | -$0.27 | -$0.29 | -$0.32 | -$0.40 | -$0.33 |